Shares of Zoetis declined 3.0% in pre-open trading following the release of the company's second-quarter 2026 results and a pared-back full-year forecast that disappointed investors.
Zoetis reported Q2 earnings per share of $1.87, just a penny above the $1.86 analyst consensus. Quarterly revenue totaled $2.5 billion, roughly flat compared with the prior year but slightly under the $2.51 billion consensus. The more consequential development for the market was management's guidance for full-year 2026 EPS of $6.15 to $6.25, which sits well below the $6.87 analyst consensus and signals that management does not expect an immediate rebound in core operations.
The guidance cut amplifies a longer-term challenge in Zoetis's U.S. companion animal segment. That business has been contending with heightened competition, more price-sensitive pet owners, and safety-related headwinds tied to the company's osteoarthritis monoclonal antibody therapies, Librela and Solensia. Together, those pressures have eroded near-term expectations for growth in the company's most important domestic franchise.
In the run-up to the print, analysts had already moderated their expectations, with recent price targets from major banks spanning $85 to $130. The results and outlook prompted further reassessment by investors.
Adding to the day’s uncertainty, Zoetis said Jay Saccaro will assume a newly combined role as Executive Vice President, Chief Financial Officer, and Chief Operating Officer, effective August 17, 2026. That leadership change introduces an additional variable for markets to weigh as the company navigates the operational and commercial challenges cited in the report.
Market-wide conditions offered limited support to the stock. The S&P 500 was marginally positive, up 0.2%, while the Nasdaq Composite slipped 0.4%, providing no sustained sector rally that might have offset company-specific weakness. Zoetis's shares are nearing a 52-week low of $71.47 after having fallen roughly half their value from a 52-week high of $160.48.
In sum, a revenue shortfall, a significant reduction to full-year EPS guidance below consensus, and a continued deterioration in the U.S. companion animal business combined to drive the pre-market decline. With the stock close to multi-year lows and expectations for full-year earnings materially adjusted downward, investors are recalibrating how quickly and how fully Zoetis might recover operationally.
Summary - Zoetis posted Q2 EPS of $1.87 versus a $1.86 consensus and revenue of $2.5 billion versus a $2.51 billion consensus. The company lowered full-year 2026 EPS guidance to $6.15–$6.25, well under the $6.87 analyst consensus. Management named Jay Saccaro to a combined EVP, CFO, and COO role effective August 17, 2026. The stock fell 3.0% pre-market and is trading near a 52-week low of $71.47.